NCT01991483

A Study of LY2928057 in Hemodialysis Participants

A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety of LY2928057 and how LY2928057 affects hemoglobin in hemodialysis participants. This study will involve multiple doses of LY2928057 given during a 6 week period either after a participant discontinues or reduces treatment to stimulate red blood cells. This study will last up to 26 weeks for each participant.

Conditions

• Renal Insufficiency, Chronic
• Kidney Disease, Chronic

Interventions

Type	Name	Description
DRUG	LY2928057	Administered intravenously
DRUG	Placebo	Administered intravenously

Timeline

• Start date: 2013-12-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2013-11-25
• Last updated: 2019-03-07
• Results posted: 2019-02-07

Locations

4 sites across 1 country: United States